ION440

Phase 2

Ionis Pharmaceuticals, Inc. (IONS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

IONSPhase 2$7.2B

ION440 Phase 2 Est. Readout

ION440• Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome48

Sep 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

View Full Landscape

Drug Information

Target Indication

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Clinical Trial

NCT06430385

Last updated: 12/5/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IONS

Ionis Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ION582Phase 3

Angelman Syndrome

OlezarsenPhase 3

Familial Chylomicronemia Syndrome

VolanesorsenPhase 3

Familial Chylomicronemia Syndrome

InotersenPhase 3

FAP

ION363Phase 3

Amyotrophic Lateral Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts